Prediction of the lenalidomide toxicity and its therapeutic efficacy in multiple myeloma patients by measuring its plasma concentration

Prediction of the lenalidomide toxicity and its therapeutic efficacy in multiple myeloma patients by measuring its plasma concentration - Prediction of the lenalidomide toxicity by measuring its plasma concentration

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000022257

Enrollment

Registered

2016-05-16

Start date

2013-07-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Multiple myeloma patient who received lenalidomide and dexamethasone

Exclusion criteria

Exclusion criteria: Multiple myeloma patient who recieved anti-cancer drugs in additon to lenalidomide

Design outcomes

Primary

Measure	Time frame
Hematological and non-hematological adverse event	—

Secondary

Measure	Time frame
Continuity of initial dosage, Hematological response	—

Countries

Japan

Contacts

Public ContactShin-ichi Fuchida

Japan Community Health care Organization Kyoto Kuramaguchi Medical Center Department of Hematology

sfuch0614@gaia.eonet.ne.jp075-441-6101

Outcome results